Lee et al. reported higher 5-year progression-free survival (65% vs. 16%) and overall survival (65% vs. 22%) in patients with p16-positive vulvar cancer when compared to the p16-negative disease [17]. This evidence concerns the gene CDKN2A and vulva cancer.